The EndoPredict Test (provided by Myriad Genetics, Inc., Salt Lake City, UT, USA), is another genomic test utilized for patients with newly diagnosed, early-stage (node negative), ER-positive and HER2-negative breast cancer. Here, ESR1 is linked to breast cancer.